| Title |
Memantine
|
|---|---|
| Published in |
Drugs, September 2012
|
| DOI | 10.2165/00003495-200666110-00015 |
| Pubmed ID | |
| Authors |
Dean M. Robinson, Gillian M. Keating |
| Abstract |
Memantine (Ebixa, Axura, Namenda, Akatinol) is a moderate-affinity, uncompetitive, voltage-dependent, NMDA-receptor antagonist with fast on/off kinetics that inhibits excessive calcium influx induced by chronic overstimulation of the NMDA receptor. Memantine is approved in the US and the EU for the treatment of patients with moderate to severe dementia of the Alzheimer's type. In well designed clinical trials, oral memantine, as monotherapy or in addition to a stable dose of acetylcholinesterase inhibitors, was well tolerated during the treatment of mild to severe Alzheimer's disease for up to 52 weeks. Memantine generally modified the progressive symptomatic decline in global status, cognition, function and behaviour exhibited by patients with moderate to severe Alzheimer's disease in four 12- to 28-week trials. In patients with mild to moderate Alzheimer's disease, data from three 24-week trials are equivocal, although meta-analyses indicate beneficial effects on global status and cognition. Memantine is an effective pharmacotherapeutic agent, and currently the only approved option, for the treatment of moderate to severe Alzheimer's disease. |
Mendeley readers
The data shown below were compiled from readership statistics for 192 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Spain | 1 | <1% |
| Canada | 1 | <1% |
| Australia | 1 | <1% |
| Unknown | 188 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 25 | 13% |
| Student > Ph. D. Student | 24 | 13% |
| Student > Master | 24 | 13% |
| Researcher | 16 | 8% |
| Other | 16 | 8% |
| Other | 26 | 14% |
| Unknown | 61 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 13% |
| Agricultural and Biological Sciences | 19 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 17 | 9% |
| Neuroscience | 16 | 8% |
| Psychology | 15 | 8% |
| Other | 33 | 17% |
| Unknown | 67 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 July 2023.
All research outputs
#8,535,472
of 25,374,647 outputs
Outputs from Drugs
#1,511
of 3,464 outputs
Outputs of similar age
#64,170
of 187,313 outputs
Outputs of similar age from Drugs
#539
of 1,379 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,464 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 187,313 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,379 others from the same source and published within six weeks on either side of this one. This one is in the 6th percentile – i.e., 6% of its contemporaries scored the same or lower than it.